Pancreatic cancer and a novel MSH2 germline alteration

11Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Objective: The objective of this study was to describe a novel MSH2 missense alteration cosegregating with pancreatic cancer. Methods: The method used was an observational study of a kindred in which a novel MSH2 missense alteration was identified. Results: We report a family in which a MSH2 P349L missense alteration is cosegregating with pancreatic cancers among 3 nonsmoking first-degree relatives. Lynch syndrome-related tumors from individuals carrying this alteration consistently showed loss of immunohistochemical expression of MSH2, and in silico analyses support the interpretation of this DNA alteration as likely pathogenic. Conclusions: The MSH2 P349L may increase the risk for pancreatic cancer beyond the usual mutations in DNA mismatch repair genes; however, studies of additional families with the identical missense alteration are needed to confirm this initial impression. Copyright © 2011 by Lippincott Williams & Wilkins.

Cite

CITATION STYLE

APA

Lindor, N. M., Petersen, G. M., Spurdle, A. B., Thompson, B., Goldgar, D. E., & Thibodeau, S. N. (2011). Pancreatic cancer and a novel MSH2 germline alteration. Pancreas, 40(7), 1138–1140. https://doi.org/10.1097/MPA.0b013e318220c217

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free